EWING, NJ--(Marketwire - December 07, 2007) - DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company") today reported the results of its recent End of Review Conference with the Food and Drug Administration (FDA) for the orBec® New Drug Application (NDA). The purpose of the meeting was to gain further clarification regarding the deficiencies noted in the October 18, 2007 not approvable letter and the data required to gain approval for orBec® for the treatment of gastrointestinal Graft-versus-Host disease (GI GVHD).
